Evaluation of multiplexed cytokine and inflammation marker measurements: A methodologic study

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 9, 2011, Pages 1902-1911

  Chaturvedi, Anil K ^a   Kemp, Troy J ^c   Pfeiffer, Ruth M ^a   Biancotto, Angelique ^d   Williams, Marcus ^c   Munuo, Stella ^b   Purdue, Mark P ^a   Hsing, Ann W ^a   Pinto, Ligia ^c   McCoy, J Philip ^d   Hildesheim, Allan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INFORMATION MANAGEMENT SERVICES INC   (United States)

^c SCIENCE APPLICATIONS INTERNATIONAL CORPORATION   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; C REACTIVE PROTEIN; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CYTOKINE; EOTAXIN; FERRITIN; FIBRINOGEN; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; HAPTOGLOBIN; INSULIN; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN 9; LEPTIN; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; PLATELET DERIVED GROWTH FACTOR BB; RANTES; RESISTIN; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN;

ARTICLE; BIO-RAD MARKER; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; LIMIT OF DETECTION; LUNG CANCER; MALE; METHODOLOGY; MILLIPORE MARKER; OVARY CANCER; PLASMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SERUM;

BIOLOGICAL MARKERS; CYTOKINES; FEMALE; HEPARIN; HUMANS; INFLAMMATION; MALE; REPRODUCIBILITY OF RESULTS;

EID: 80052525379     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0221     Document Type: Article

References (22)

1. Moss S.F., Blaser M.J. Mechanisms of disease: Inflammation and the origins of cancer. Nat Clin Pract Oncol 2005;2:90-97 (Pubitemid 40790142)
2. Thun M.J., Henley S.J., Gansler T. Inflammation and cancer: An epidemiological perspective. Novartis Found Symp 2004;256:6-21.
3. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002;420:860-867 (Pubitemid 36019639)
4. De Visser K.E., Coussens L.M. The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 2006;13:118-137
5. Heikkila K., Harris R., Lowe G., Rumley A., Yarnell J., Gallacher J., et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: Findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009;20:15-26.
6. Elshal M.F., McCoy J.P. Multiplex bead array assays: Performance evaluation and comparison of sensitivity to ELISA. Methods 2006;38:317-323
7. de JW, Rijkers GT. Solid-phase and bead-based cytokine immunoassay: A comparison. Methods 2006;38:294-303.
8. Hosnijeh F.S., Krop E.J., Portengen L., Rabkin C.S., Linseisen J., Vineis P., et al. Stability and reproducibility of simultaneously detected plasma and serum cytokine levels in asymptomatic subjects. Biomarkers 2010;15:140-148
9. Wong H.L., Pfeiffer R.M., Fears T.R., Vermeulen R., Ji S., Rabkin C.S. Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiol Biomarkers Prev 2008;17:3450-3456
10. Gu Y., Zeleniuch-Jacquotte A., Linkov F., Koenig K.L., Liu M., Velikokhatnaya L., et al. Reproducibility of serum cytokines and growth factors. Cytokine 2009;45:44-49
11. Chowdhury F., Williams A., Johnson P. Validation and comparison of two multiplex technologies, Luminex((R)) and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods 2009;340:55-64.
12. Khan S.S., Smith M.S., Reda D., Suffredini A.F., McCoy J.P. Jr. Multiplex bead array assays for detection of soluble cytokines: Comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom 2004;61:35-39 (Pubitemid 39223368)
13. Djoba Siawaya J.F., Roberts T., Babb C., Black G., Golakai H.J., Stanley K., et al. An evaluation of commercial fluorescent bead-based luminex cytokine assays. PLoS One 2008;3:e2535.
14. dupont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: Determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol 2005;66:175-191
15. Fu Q., Zhu J., Van Eyk J.E. Comparison of multiplex immunoassay platforms. Clin Chem 2010;56:314-318
16. Hayes R.B., Sigurdson A., Moore L., Peters U., Huang W.Y., Pinsky P., et al. Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res 2005;592:147-154 (Pubitemid 41714051)
17. Kemp T.J., Hildesheim A., Garcia-Pineres A., Williams M.C., Shearer G.M., Rodriguez A.C., et al. Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection. Cancer Epidemiol Biomarkers Prev 2010;19:1954-1959
18. Aziz N., Nishanian P., Mitsuyasu R., Detels R., Fahey J.L. Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol 1999;6:89-95. (Pubitemid 29035646)
19. Tworoger S.S., Hankinson S.E. Use of biomarkers in epidemiologic studies: Minimizing the influence of measurement error in the study design and analysis. Cancer Causes Control 2006;17:889-899 (Pubitemid 44078280)
20. Toedter G., Hayden K., Wagner C., Brodmerkel C. Simultaneous detection of eight analytes in human serum by two commercially available platforms for multiplex cytokine analysis. Clin Vaccine Immunol 2008;15:42-48 (Pubitemid 351966532)
21. O'Connor M.F., Irwin M.R. Links between behavioral factors and inflammation. Clin Pharmacol Ther 2010;87:479-482
22. Platz E.A., Sutcliffe S., De Marzo A.M., Drake C.G., Rifai N., Hsing A.W., et al. Intra-individual variation in serum C-reactive protein over 4 years: An implication for epidemiologic studies. Cancer Causes Control 2010;21:847-851